Unable to display view head.php file not found.
 
American Journal of Medicine
 

Eikelboom - Evidence from the Randomized Trials - Figure 24
AMPLIFY Ext: VTE or VTE-related Deaths

The primary results of apixaban for the outcome of VTE or VTE-related mortality in the AMPLPIFY-EXT trial showed that both doses of apixaban very substantially reduced the risk of recurrence by around 80% (Figure 24) .[14]  Eikelboom J. Am J Med 2013; published on-line at http://education.amjmed.com/00000. 

References

[14] Agnelli G, Büller HR, Cohen A, et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699-708.

Unable to display view foot.php file not found.